These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28737440)

  • 1. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis.
    Feldman SR; Green L; Kimball AB; Siu K; Zhao Y; Herrera V; Nyirady J; Alexis AF
    J Dermatolog Treat; 2017 Dec; 28(8):716-721. PubMed ID: 28737440
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: results of two phase 3, randomized, placebo-controlled clinical trials.
    Strober B; Sigurgeirsson B; Popp G; Sinclair R; Krell J; Stonkus S; Septe M; Elewski BE; Gottlieb AB; Zhao Y; Tran MH; Karpov A; McLeod LD; Mordin M; Papavassilis C; Nyirady J; Lebwohl M
    Int J Dermatol; 2016 Apr; 55(4):401-7. PubMed ID: 26866518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study.
    Puig L; Augustin M; Blauvelt A; Gottlieb AB; Vender R; Korman NJ; Thaçi D; Zhao Y; Gilloteau I; Sherif B; Williams N; Guana A; Lebwohl MG
    J Am Acad Dermatol; 2018 Apr; 78(4):741-748. PubMed ID: 29066271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study.
    Bagel J; Duffin KC; Moore A; Ferris LK; Siu K; Steadman J; Kianifard F; Nyirady J; Lebwohl M
    J Am Acad Dermatol; 2017 Oct; 77(4):667-674. PubMed ID: 28780364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential effects of secukinumab vs. ustekinumab for treatment of psoriasis on quality of life, work productivity and activity impairment: a structural equation modelling analysis.
    Stull DE; Griffiths CEM; Gilloteau I; Zhao Y; Guana A; Finlay AY; Sherif B; Houghton K; Puig L
    Br J Dermatol; 2018 Jun; 178(6):1297-1307. PubMed ID: 29355896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study.
    Blauvelt A; Reich K; Tsai TF; Tyring S; Vanaclocha F; Kingo K; Ziv M; Pinter A; Vender R; Hugot S; You R; Milutinovic M; Thaçi D
    J Am Acad Dermatol; 2017 Jan; 76(1):60-69.e9. PubMed ID: 27663079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of efalizumab on psoriasis-specific patient-reported outcomes. Results from three randomized, placebo-controlled clinical trials of moderate to severe plaque psoriasis.
    Menter A; Kosinski M; Bresnahan BW; Papp KA; Ware JE
    J Drugs Dermatol; 2004; 3(1):27-38. PubMed ID: 14964744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.
    Korman NJ; Sofen H; Fretzin S; Rich P; Zhao Y; Herrera V; Nyirady J; Williams N; Mordin M; Tyring S
    J Dermatolog Treat; 2017 Aug; 28(5):384-389. PubMed ID: 27832717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: Results of the 2PRECISE study.
    Mrowietz U; Bachelez H; Burden AD; Rissler M; Sieder C; Orsenigo R; Chaouche-Teyara K
    J Am Acad Dermatol; 2019 May; 80(5):1344-1352. PubMed ID: 30716404
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results.
    Augustin M; Dauden E; Mrowietz U; Konstantinou MP; Gerdes S; Kingo K; Szepietowski JC; Perrot JL; Cuccia A; Rissler M; Gathmann S; Sieder C; Orsenigo R; Jagiello P; Bachhuber T
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):431-440. PubMed ID: 32426889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept.
    Strober B; Gottlieb AB; Sherif B; Mollon P; Gilloteau I; McLeod L; Fox T; Mordin M; Gnanasakthy A; Papavassilis C; Lebwohl MG
    J Am Acad Dermatol; 2017 Apr; 76(4):655-661. PubMed ID: 28087133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased severity of itching, pain, and scaling in psoriasis patients is associated with increased disease severity, reduced quality of life, and reduced work productivity.
    Korman NJ; Zhao Y; Pike J; Roberts J; Sullivan E
    Dermatol Online J; 2015 Oct; 21(10):. PubMed ID: 26632793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pruritus and quality of life in moderate-to-severe plaque psoriasis: post hoc explorative analysis from the PRISTINE study.
    Mrowietz U; Chouela EN; Mallbris L; Stefanidis D; Marino V; Pedersen R; Boggs RL
    J Eur Acad Dermatol Venereol; 2015 Jun; 29(6):1114-20. PubMed ID: 25376448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study.
    Blauvelt A; Reich K; Mehlis S; Vanaclocha F; Sofen H; Abramovits W; Zhao Y; Gilloteau I; Davenport E; Williams N; Guana A; Tyring S
    J Eur Acad Dermatol Venereol; 2017 Oct; 31(10):1693-1699. PubMed ID: 28602039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.
    Kimball AB; Bensimon AG; Guerin A; Yu AP; Wu EQ; Okun MM; Bao Y; Gupta SR; Mulani PM
    Am J Clin Dermatol; 2011 Feb; 12(1):51-62. PubMed ID: 21110526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
    Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
    Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of secukinumab on the clinical activity and disease burden of nail psoriasis: 32-week results from the randomized placebo-controlled TRANSFIGURE trial.
    Reich K; Sullivan J; Arenberger P; Mrowietz U; Jazayeri S; Augustin M; Parneix A; Regnault P; You R; Milutinovic M
    Br J Dermatol; 2019 Nov; 181(5):954-966. PubMed ID: 30367462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139].
    Ortonne JP; Shear N; Shumack S; Henninger E;
    BMC Dermatol; 2005 Dec; 5():13. PubMed ID: 16359548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis patients with psoriasis Area and Severity Index (PASI) 90 response achieve greater health-related quality-of-life improvements than those with PASI 75-89 response: results from two phase 3 studies of secukinumab.
    Elewski BE; Puig L; Mordin M; Gilloteau I; Sherif B; Fox T; Gnanasakthy A; Papavassilis C; Strober BE
    J Dermatolog Treat; 2017 Sep; 28(6):492-499. PubMed ID: 28266243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secukinumab efficacy and safety in Japanese patients with moderate-to-severe plaque psoriasis: subanalysis from ERASURE, a randomized, placebo-controlled, phase 3 study.
    Ohtsuki M; Morita A; Abe M; Takahashi H; Seko N; Karpov A; Shima T; Papavassilis C; Nakagawa H;
    J Dermatol; 2014 Dec; 41(12):1039-46. PubMed ID: 25354738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.